<DOC>
	<DOCNO>NCT00030524</DOCNO>
	<brief_summary>RATIONALE : Biological therapy ZD 1839 may interfere growth tumor cell slow growth colorectal cancer . PURPOSE : Phase II trial study effectiveness ZD 1839 treat patient locally advance metastatic colorectal cancer respond chemotherapy .</brief_summary>
	<brief_title>ZD 1839 Treating Patients With Locally Advanced Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine progression-free rate 16 week , response rate , time treatment failure , survival patient treat gefitinib locally advanced metastatic colorectal adenocarcinoma refractory fluorouracil , irinotecan , capecitabine . - Correlate pharmacodynamic effect drug index clinical benefit ( e.g. , tumor growth inhibition , time tumor progression , survival ) patient . - Determine whether status epidermal growth factor receptor activation signal predictive clinical outcome patient treat drug . OUTLINE : This multicenter study . Patients receive oral gefitinib daily . Treatment continue every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 18-46 patient accrue study within 5-12 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm colorectal adenocarcinoma Metastatic locally advance disease Not amenable curative therapy Documentation disease progression within past 6 month Previously treat fluoropyrimidine irinotecanbased chemotherapy ( include capecitabine ) administer either concurrently ( 2 regimen ) sequentially ( 3 regimen ) advance disease At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR least 10 mm spiral CT scan No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : More 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 3 time ULN ( 5 time ULN liver metastasis present ) Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Ophthalmic : No significant ophthalmic condition , include : Severe dryeye syndrome Keratoconjunctivitis sicca Sjogren 's syndrome Severeexposure keratopathy Disorders may increase risk epitheliumrelated complication ( e.g. , bullous keratopathy , aniridia , severe chemical burn , neutrophilic keratitis ) Other : Able take oral gefitinib No uncontrolled concurrent illness No ongoing active infection No psychiatric illness social situation would preclude study participation No prior gastrointestinal disorder ( e.g. , malabsorption syndrome ) No prior allergic reaction attribute compound similar chemical biological composition gefitinib No prior malignancy except carcinoma situ cervix , nonmelanoma skin cancer , cancer patient free evident disease 5 year and/or less 2030 % estimate likelihood recurrence Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 30 day since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : No prior gastric resection Other : No prior therapy advance disease No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational commercial agent therapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>